Use of recombinant factor VIIa for hip surgery in a patient with factor-VII deficiency: A case report

Journal of Bone and Joint Surgery

Volumn 89, Issue 2, 2007, Pages 389-391

  Gopalan, Priya K ^a   Clohisy, John C ^a   Cashen, Amanda F ^a   Eby, Charles S ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BLOOD CLOTTING FACTOR 7; FRESH FROZEN PLASMA; RECOMBINANT BLOOD CLOTTING FACTOR 7A; VITAMIN K GROUP;

AGED; AGED HOSPITAL PATIENT; ARTICLE; BLEEDING; BLOOD CLOTTING FACTOR 7 DEFICIENCY; CASE REPORT; DEEP VEIN THROMBOSIS; DRUG DOSE REDUCTION; ENDOPROSTHESIS LOOSENING; FOLLOW UP; HEMATOMA; HIP SURGERY; HUMAN; LEG COMPRESSION; MALE; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; REPEATED DRUG DOSE; TOTAL HIP PROSTHESIS; TREATMENT OUTCOME; WOUND INFECTION;

EID: 33846839272     PISSN: 00219355     EISSN: None     Source Type: Journal    
DOI: 10.2106/00004623-200702000-00023     Document Type: Article

References (15)

1. Perry DJ. Factor VII deficiency. Br J Haematol. 2002;118:689-700.
2. Bauer KA. Treatment of factor VII deficiency with recombinant factor VIIa. Haemostasis. 1996;26 Suppl 1:155-8.
3. Uhlmann EJ, Eby CS. Recombinant activated factor VII for non-hemophiliac bleeding patients. Curr Opin Hematol. 2004;11:198-204.
4. Midathada MV, Mehta P, Waner M, Fink LM. Recombinant factor VIIa in the treatment of bleeding. Am J Clin Pathol. 2004;121:124-37.
5. Levi M, Peters M, Buller HR. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit Care Med. 2005;33:883-90.
6. Mariani G, Testa MG, Di Paolantonio T, Molskov Bech R, Hedner U. Use of recombinant, activated factor VII in the treatment of congenital factor VII deficiencies. Vox Sang. 1999;77:131-6.
7. Perez R, Martinez RL, Pinero A, Sosa R. Sequential treatment with bolus and continuous infusion of recombinant factor VIIa for hip arthroplasty in a patient with haemophilia A and inhibitor. Haemophilia. 2002;8:822-5.
8. Ludlam CA, Smith MP, Morfini M, Gringeri A, Santagostino E, Savidge GF. A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: a pharmacokinetic and efficacy evaluation. Br J Haematol. 2003;120:808-13.
9. Slappendel R, Huvers FC, Benraad B, Novakova I, van Hellemondt GG. Use of recombinant factor Vila (NovoSeven) to reduce postoperative bleeding after total hip arthroplasty in a patient with cirrhosis and thrombocytopenia. Anesthesiology. 2002;96:1525-7.
10. Ingerslev J, Knudsen L, Hvid I, Tange MR, Fredberg U, Sneppen O. Use of recombinant factor VIIa in surgery in factor-VII-deficient patients. Haemophilia. 1997;3:215-8.
11. Niikura T, Nishikawa T, Saegusa Y, Fujishiro T, Yoshiya S, Kurosaka M. Total hip arthroplasty in severe congenital factor VII deficiency: successful use of recombinant activated factor VII for hemostasis. J Arthroplasty. 2005;20:396-400.
12. Roberts HR, Monroe DM, White GC. The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood. 2004;104:3858-64. Erratum in: Blood. 2005;105:2257.
13. Roberts HR, Monroe DM 3rd, Hoffman M. Safety profile of recombinant factor VIIa. Semin Hematol. 2004;41(1 Suppl 1):101-8.
14. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, Skolnick BE, Steiner T; Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2005;352:777-85.
15. Goodnough LT, Lublin DM, Zhang L, Despotis G, Eby C. Transfusion medicine service policies for recombinant factor VIIa administration. Transfusion. 2004;44:1325-31.